The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I):
tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
CONDENSED TRICYCLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS
申请人:Vertex Pharmaceuticals Incorporated
公开号:EP3969440A1
公开(公告)日:2022-03-23
[EN] MODULATORS OF ALPHA-1 ANTITRYPSIN<br/>[FR] MODULATEURS DE L'ALPHA -1 ANTITRYPSINE
申请人:VERTEX PHARMA
公开号:WO2020081257A1
公开(公告)日:2020-04-23
Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
[EN] CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS<br/>[FR] PYRROLES TRICYCLIQUES CONDENSÉS UTILISÉS COMME MODULATEURS DE L'ALPHA-1 ANTITRYPSINE
申请人:VERTEX PHARMA
公开号:WO2020247160A1
公开(公告)日:2020-12-10
The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.